Peter V. D. B.
- Country
- The Netherlands
- Department
- Hematology
Research Overview
- Phase 3 Evaluation of Daratumumab with Bortezomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Untreated Multiple Myeloma
- Evaluation of Revumenib Combined with Azacitidine and Venetoclax in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML Patients Ineligible for Intensive Chemotherapy
- Phase 3 Randomized Open-Label Study of Axatilimab Versus Best Available Therapy in Chronic Graft-Versus-Host Disease Post Two Systemic Therapy Lines
Data & Insights
Has run more than one trial at 77 of 228 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating blood-based cancers, with particular emphasis on Multiple Myeloma and Acute Myeloid Leukemia. Their research interests encompass innovative therapeutic approaches for these conditions.
- Multiple Myeloma Treatment Protocols
- AML Management Strategies
- Novel Combination Therapies
A key focus is on developing treatment solutions for newly diagnosed patients.
Therapeutic Innovation
The investigator explores novel drug combinations involving agents such as daratumumab, bortezomib, and revumenib. Their work includes evaluation of targeted therapies for specific genetic mutations.
- Combination Drug Protocols
- Targeted Therapeutic Approaches
- Treatment Optimization
Their research emphasizes personalized treatment strategies based on genetic markers.
Patient Care Advancement
The investigator focuses on developing treatments for distinct patient populations, including those with NPM1-mutated AML and patients unsuitable for intensive chemotherapy regimens.
- Treatment Adaptation
- Patient-Specific Protocols
- Alternative Treatment Options
Their work aims to expand therapeutic options for diverse patient groups.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.